{"id":2050,"date":"2025-10-16T16:42:38","date_gmt":"2025-10-16T16:42:38","guid":{"rendered":"https:\/\/retrotradingreport.com\/index.php\/2025\/10\/16\/whats-fueling-prax-stocks-jaw-dropping-235-surge-on-thursday\/"},"modified":"2025-10-16T16:42:38","modified_gmt":"2025-10-16T16:42:38","slug":"whats-fueling-prax-stocks-jaw-dropping-235-surge-on-thursday","status":"publish","type":"post","link":"https:\/\/retrotradingreport.com\/index.php\/2025\/10\/16\/whats-fueling-prax-stocks-jaw-dropping-235-surge-on-thursday\/","title":{"rendered":"What\u2019s fueling PRAX stock\u2019s jaw-dropping 235% surge on Thursday?"},"content":{"rendered":"
<\/div>\n

Praxis Precision Medicines (NASDAQ: PRAX stock) saw a skyrocketing 235% rally on Thursday after announcing positive topline results from two pivotal Phase 3 studies of ulixacaltamide for essential tremor, a common movement disorder.<\/p>\n

The exceptional rally attracted considerable investor interest as it came with heavy trading volume and premarket gains, making it perfect for traders looking to make big on $10K or more worth of bets.<\/p>\n

This breakthrough has investors pricing in a potential blockbuster treatment for the condition affecting millions.<\/p>\n

PRAX stock: What the Phase-3 data actually shows<\/h2>\n

Praxis Therapeutics shared some pretty exciting news about its experimental drug, ulixacaltamide, and the results look very promising.<\/p>\n

In Study 1, a parallel-group trial, patients taking ulixacaltamide showed a mean improvement of 4.3 points on the Modified Activities of Daily Living 11 (mADL11) scale after eight weeks, the main goal of the study.<\/p>\n

That\u2019s a pretty solid result, backed by a highly significant p-value of less than 0.0001. In simple terms, the data was statistically rock-solid.<\/p>\n

That means patients and clinicians both saw clear improvements.<\/p>\n

Then there\u2019s Study 2, which used a randomized-withdrawal design.<\/p>\n

It also met its main goal, showing that patients who stayed on ulixacaltamide maintained their progress better than those switched to placebo during the withdrawal phase.<\/p>\n

The study also found continued improvements in the rate of disease progression.<\/p>\n

On the safety side, the results were reassuring; no drug-related serious adverse events were reported, which is consistent with earlier trials.<\/p>\n

Praxis CEO Marcio Souza emphasized how big this could be for people living with essential tremor, a common and often debilitating movement disorder.<\/p>\n

He pointed out that more than 200,000 people expressed interest in joining the study, a sign of just how much unmet need there is for better treatments.<\/p>\n

Souza said these results underscore ulixacaltamide\u2019s potential to make a real difference for patients who\u2019ve been waiting far too long for effective options.<\/p>\n

Volume, analyst moves and what\u2019s priced in<\/h2>\n

Following the upbeat clinical news, PRAX stock absolutely exploded on Thursday, soaring more than 235% intraday.<\/p>\n

Shares shot up to around $172.35, compared to the previous day\u2019s close of about $57.35, a jaw-dropping move that had traders buzzing.<\/p>\n

Trading activity was off the charts too, with roughly 5.9 million shares changing hands, way above its usual daily average of just 466,000.<\/p>\n

Even before the market opened, the enthusiasm was building.<\/p>\n

Analysts were quick to weigh in with upbeat takes.<\/p>\n

Piper Sandler<\/a> reaffirmed its Overweight rating and slapped a $270 price target on the stock, pointing to the strong Phase 2 and Phase 3 data and key upcoming catalysts, especially the anticipated NDA (New Drug Application) submission.<\/p>\n

According to TipRanks<\/a>, the broader analyst community is on the same page: PRAX holds a \u201cStrong Buy\u201d consensus, with an average price target hovering around $270.<\/p>\n

That optimism reflects growing confidence in the commercial potential of ulixacaltamide and its ability to be a game-changer in neurological disorders.<\/p>\n

The post What\u2019s fueling PRAX stock\u2019s jaw-dropping 235% surge on Thursday?<\/a> appeared first on Invezz<\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Praxis Precision Medicines (NASDAQ: PRAX stock) saw a skyrocketing 235% rally on Thursday after announcing positive topline results from two pivotal Phase 3 studies of ulixacaltamide for essential tremor, a common movement disorder.The exceptional rally attracted considerable investor interest as it came with heavy trading volume and premarket gains, making it perfect for traders looking…<\/p>\n","protected":false},"author":1,"featured_media":2051,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-2050","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investing"],"_links":{"self":[{"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/posts\/2050","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/comments?post=2050"}],"version-history":[{"count":0,"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/posts\/2050\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/media\/2051"}],"wp:attachment":[{"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/media?parent=2050"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/categories?post=2050"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/tags?post=2050"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}